Active ingredientAficamtenCat. No. P-A050-001CAS 2364554-48-1Family · Pharmaceutical analytical standards
Aficamten
An oral cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, approved in the United States in December 2025 and in the European Union in February 2026. This family brings together the active ingredient.
Did you know?Myosin is the molecular motor of contraction: aficamten stops it entering its force-producing state, easing the excessive contraction of the thickened heart and the obstruction to blood outflow.
Go to the active ingredient →Active ingredientAficamtenCat. No. P-A050-001CAS 2364554-48-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.